NasdaqCM - Nasdaq Real Time Price USD

Intelligent Bio Solutions Inc. (INBS)

Compare

1.3100

0.0000

(0.00%)

At close: January 16 at 4:00:00 PM EST

1.3000

-0.01

(-0.76%)

After hours: January 16 at 6:57:53 PM EST

Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites

Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market in the first half of the 2025 calendar yearNEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Princebuild, a leading construction firm with seven sites and operations spanning six key divisions, has adopted

GlobeNewswire 2 days ago

INBS
0.00%
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

INBS Intelligent Fingerprinting Drug Screening System INBS' non-invasive, cost-effective drug screening solution NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprint

GlobeNewswire 29 days ago

INBS
0.00%
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024. During the event, management will discuss the Company's recent clinical study results, path to FDA 510(k) submission, and offer investors

GlobeNewswire last month

INBS
0.00%
Intelligent Bio Solutions completes fingerprint drug screening system study

The company anticipates introducing its fingerprint sweat-based drug screening technology by next year.

Medical Device Network last month

INBS
0.00%
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its m

GlobeNewswire last month

INBS
0.00%
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL. Noble Capital Markets’ 20th Annual Emerging Growth Equity ConferenceDates: December 3-4, 2024Location: Florida

GlobeNewswire last month

INBS
0.00%
INBS Stock Declines Despite Positive Results of Pharmacokinetic Study

Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.

Zacks last month

INBS
0.00%
ANGO

GMED
Intelligent gears up for FDA approval of fingerprint drug detection device

The pharmacokinetics study showed that fingerprint sweat provides a reliable and comparable sample matrix for drug detection as blood.

Medical Device Network 2 months ago

INBS
0.00%
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced strong initial results from its Pharmacokinetic (PK) study required for an FDA 510(k

GlobeNewswire 2 months ago

INBS
0.00%
Intelligent Bio Solutions First Quarter 2025 Earnings: US$0.70 loss per share (vs US$12.49 loss in 1Q 2024)

Intelligent Bio Solutions ( NASDAQ:INBS ) First Quarter 2025 Results Key Financial Results Revenue: US$872.3k (up 9.6...

Simply Wall St. 2 months ago

INBS
0.00%
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue as primary driver Completed in-clinic portion of FDA 510(k) clinical study plan, on track to submit to FDA by year-end Expanded distribution network in Saudi Arabia Initial review of PK study results show fingerprint sweat strongly aligns to blood and oral fluid, results expected in November NEW YORK,

GlobeNewswire 2 months ago

INBS
0.00%
Intelligent Bio Solutions Partners With B2i Digital to Amplify Investor Outreach

NEW YORK - (NewMediaWire) - November 1, 2024 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnershi...

NewMediaWire 2 months ago

INBS
0.00%
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver Expanded distribution network in Saudi Arabia NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fisca

GlobeNewswire 2 months ago

INBS
0.00%
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil

Developer Praises Intelligent Bio Solutions’ Innovative Drug Testing Solution for Improving Workplace SafetyNEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today announced that its customer Mount Anvil, one of London's most respected property developers, has celebrated its one-year anniversary of enhanced workplace safety after integrating INBS’ Intell

GlobeNewswire 2 months ago

INBS
0.00%
Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles

New York, New York--(Newsfile Corp. - October 16, 2024) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present in the upcoming LD Micro Main Event XVII on October 28-30, 2024, in Los Angeles.LD Micro Main Event XVIIDates: October 28-30, 2024Location: Luxe Sunset Boulevard Hotel, Los Angeles, CAPresentation Day and Time: October 30 a

Newsfile 2 months ago

INBS
0.00%
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

Transition will Minimize Downtime, Deliver Faster, More Cost-Effective Results, and Improve Overall Safety and ProductivityNEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions, today announced the addition of Pyrotek Pty Ltd (“Pyrotek”), to its customer base. Pyrotek is a global leader in engineering solutions. By adopting INBS’ Intelligent Fingerprinting Dr

GlobeNewswire 3 months ago

INBS
0.00%
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency, with prominent clients across a wide range of industries, including mining, transportation and construction. Spirit Group will bring INBS’ Intelligent Fingerprint

GlobeNewswire 3 months ago

INBS
0.00%
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts. GPS Marine delivers critical maritime services across the UK’s inland waterways and coastal regions. With decades of experience, GPS Mari

GlobeNewswire 3 months ago

INBS
0.00%
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of in-clinic testing proposed to the FDA earlier this year in the Company’s clinical study plan. The clinical studies are a key element of the Company's 510(k) submission, designed to demonstrate the accuracy and reliability of its sweat-based test

GlobeNewswire 3 months ago

INBS
0.00%
UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Thanet Earth, the UK’s largest greenhouse complex, has adopted its Intelligent Fingerprinting Drug Screening System for in-house drug testing. “We are thrilled to partner with Intelligent Fingerprinting to enhance our approach to workplace safety,” said Emma Bullock, H

GlobeNewswire 3 months ago

INBS
0.00%

Performance Overview

Return	INBS	S&P 500
YTD	-4.38%	+0.51%
1-Year	-61.43%	+24.11%
3-Year	-99.65%	+27.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Intelligent Bio Solutions Inc. (INBS)

Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites

Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

Intelligent Bio Solutions completes fingerprint drug screening system study

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

INBS Stock Declines Despite Positive Results of Pharmacokinetic Study

Intelligent gears up for FDA approval of fingerprint drug detection device

Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

Intelligent Bio Solutions First Quarter 2025 Earnings: US$0.70 loss per share (vs US$12.49 loss in 1Q 2024)

Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

Intelligent Bio Solutions Partners With B2i Digital to Amplify Investor Outreach

Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results

Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil

Intelligent Bio Solutions to Present at the LD Micro Main Event XVII on October 28-30 in Los Angeles

Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek

Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution

GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission

UK’s Largest Greenhouse Complex, Thanet Earth, Adopts Intelligent Bio Solutions’ Fingerprint Drug Test to Enhance Workplace Safety

Performance Overview